STL Index for: Afamelanotide

Update on Drugs & Devices: November – December 2019

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

Index for STL Volume 23 (2018)

Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references. Use the main navigation (A, B, C..) to navigate through this index and use the reference links (i.e. 4:5-9) to see the sources.

Afamelanotide in the Treatment of Dermatologic Disease

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments.

Skin Treatments Introduced in 2014

An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.

Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

POPULAR